Scholarlink

<p><i>NRF2</i> modulates tumor immune microenvironment in several cancers. NRF2 is activated in about 50% of high-grade serous ovarian cancer (HGSOC), the most aggressive type of ovarian cancer. Through analyzing data from scRNA-seq (<i>n</i> = 7), bulk RNA-seq (<i>n</i> = 365), and tumor microarray (TMA) of human HGSOC (<i>n</i> = 240) samples, we demonstrated that NRF2 expression correlated with tumor immune microenvironment in HGSOC. Functional pathway enrichment analysis and transcription factors (TFs) prediction showed the functional relevance of NRF2 expression in shaping the immune phenotype of HGSOC. Pathways such as hedgehog and ROS signaling, and TFs including EGR1, ESRRA, SMAD proteins, and SP-family proteins, are implicated in the immune suppressive microenvironment of NRF2<sup>High</sup> tumors. Immune differentiation analysis showed patients with NRF2<sup>High</sup> tumors enriched with CD68 have lower survival (<i>p</i> = 0.038) than those with CD68<sup>Low</sup> tumors, whereas NRF2<sup>Low</sup> tumors enriched with immune-activated markers such as CD3E and CD80 exhibit a better prognosis. This study is the first that shows classification of HGSOC based on NRF2 levels, highlights new biomarkers, and suggests IHC-labeling and genomic evaluation of NRF2 and immune markers for better prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer

  • 期刊论文

  • 发表日期：

    2026年4月28日

查看全文
  • Samera H. Hamad,
  • Chelsea Katz,
  • Helen Toma,
  • Kosuke Murakami,
  • Nasrine Bendjilali,
  • Gord Zhu,
  • Hadi Shojaei,
  • Lanlan Fang,
  • Samuel Leung,
  • Martin Koebel,
  • Huseyin Karaduman,
  • Oliver Abinader,
  • Ramkrishna Mitra,
  • Lauren Krill,
  • Christina Chu,
  • David P. Warshal,
  • Yemin Wang

摘要

NRF2 modulates tumor immune microenvironment in several cancers. NRF2 is activated in about 50% of high-grade serous ovarian cancer (HGSOC), the most aggressive type of ovarian cancer. Through analyzing data from scRNA-seq (n = 7), bulk RNA-seq (n = 365), and tumor microarray (TMA) of human HGSOC (n = 240) samples, we demonstrated that NRF2 expression correlated with tumor immune microenvironment in HGSOC. Functional pathway enrichment analysis and transcription factors (TFs) prediction showed the functional relevance of NRF2 expression in shaping the immune phenotype of HGSOC. Pathways such as hedgehog and ROS signaling, and TFs including EGR1, ESRRA, SMAD proteins, and SP-family proteins, are implicated in the immune suppressive microenvironment of NRF2High tumors. Immune differentiation analysis showed patients with NRF2High tumors enriched with CD68 have lower survival (p = 0.038) than those with CD68Low tumors, whereas NRF2Low tumors enriched with immune-activated markers such as CD3E and CD80 exhibit a better prognosis. This study is the first that shows classification of HGSOC based on NRF2 levels, highlights new biomarkers, and suggests IHC-labeling and genomic evaluation of NRF2 and immune markers for better prognosis.